Core Insights - Nurix Therapeutics has initiated the DAYBreak™ registrational program for bexobrutideg in relapsed/refractory chronic lymphocytic leukemia (CLL), supported by promising Phase 1 clinical data showing an 83% objective overall response rate and a median progression-free survival of 22.1 months [1][4][5] - The company reported financial results for the fiscal quarter ending November 30, 2025, highlighting a revenue increase to $84 million for the year, primarily due to $30 million in license revenue from Sanofi [2][19] - Nurix has a strong cash position with $592.9 million in cash and marketable securities, enabling continued investment in clinical programs and pipeline expansion [1][23] Clinical Development - Bexobrutideg demonstrated durable therapeutic effects in heavily pretreated CLL patients, achieving a median duration of response of 20.1 months across all doses tested [4] - The ongoing Phase 1b cohort showed higher response rates and a favorable trend toward longer progression-free survival at the 600 mg dose, which has been selected as the recommended Phase 2 dose [4][5] - Encouraging Phase 1 data for bexobrutideg in Waldenström macroglobulinemia (WM) showed a 75% objective response rate, reinforcing its potential as a therapeutic option across BTK-driven B-cell malignancies [6][7] Financial Performance - Revenue for the fiscal year ended November 30, 2025, was $84 million, up from $54.5 million in the previous year, driven by collaboration milestones and license revenue [19] - Research and development expenses increased to $316.9 million for the year, reflecting accelerated clinical trial activities [20] - The net loss for the year was $264.5 million, compared to $193.6 million in the previous year, with a net loss per share of $3.05 [23] Strategic Collaborations - Nurix is advancing its IRAK4 degrader program (GS-6791) in collaboration with Gilead, with promising preclinical data supporting its potential in autoimmune and inflammatory diseases [9] - The company continues to strengthen its collaborations with Sanofi and Pfizer, focusing on the development of targeted protein degradation medicines [21] Upcoming Initiatives - Nurix plans to initiate a global randomized confirmatory Phase 3 trial in the first half of 2026 to support full approval of bexobrutideg [14] - The company is also enrolling patients in a Phase 1b cohort for bexobrutideg in autoimmune hemolytic anemia, aiming to expand its therapeutic applications [15]

Bexobrutideg Clinical Trial and Data - Bexobrutideg achieved an 83% objective response rate (ORR) in relapsed/refractory CLL patients in Phase 1a trials[8, 26, 32, 40] - The median progression-free survival (PFS) for Bexobrutideg was 22.1 months across all doses tested in the Phase 1a study[8, 26, 32, 40] - In a Phase 1b randomized cohort, the 600 mg dose of Bexobrutideg showed an 83.3% objective response rate[37, 38] - Nurix initiated the pivotal DAYBreak-201 Phase 2 study to support accelerated approval of bexobrutideg in relapsed/refractory CLL[8, 43] - A confirmatory Phase 3 trial is planned to start in 2026 to position Bexobrutideg for full approval[58] Pipeline and Partnerships - Nurix has a strengthened financial position with $663.8 million in pro forma cash/investments[8] - Nurix earned $47 million in non-dilutive capital through discovery partnerships[8] - The IRAK4 degrader is in an ongoing Phase 1 SAD/MAD study with partner Gilead[8, 9] - The STAT6 degrader advanced to IND-enabling studies with partner Sanofi[8, 9] Bexobrutideg Mechanism and Advantages - Bexobrutideg is a BTK degrader that removes both BTK enzymatic activity and scaffolding functions, unlike BTK inhibitors[10, 12] - Bexobrutideg demonstrates superior mutational coverage compared to BTK inhibitors[19, 20] - Bexobrutideg is the only BTK degrader to demonstrate clinical activity in patients with CNS disease, including complete responses[22] Market and Strategy - The current BTK inhibitor market is annualizing at $12.5 billion, with approximately $9.5 billion in CLL[55] - Nurix has a clinical development plan addressing large segments of the CLL market as both a mono- and combo- therapy[54]

Bexobrutideg Investor Update Investor Presentation October 2025 Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company's own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any infor ...

Core Insights - Nurix Therapeutics is advancing its clinical development plans for bexobrutideg, targeting relapsed/refractory chronic lymphocytic leukemia (CLL) with pivotal trials set to begin in the second half of 2025 [1][2] - The company reported a cash position of $428.8 million as of August 31, 2025, indicating strong capitalization for ongoing and future projects [1][8] Clinical Development - Bexobrutideg is set to undergo a single-arm study for potential accelerated approval in relapsed/refractory CLL patients, alongside a randomized controlled Phase 3 trial [2] - Preclinical data for GS-6791, an IRAK4 degrader developed in collaboration with Gilead, demonstrated significant efficacy in a dermatitis model, showcasing its potential in autoimmune diseases [1][2] - Recent Phase 1a data for bexobrutideg in CLL showed an overall response rate (ORR) of 80.9% among 47 evaluable patients, with rapid responses and durable activity noted [2][3] Financial Performance - Revenue for the fiscal quarter ended August 31, 2025, was $7.9 million, a decrease from $12.6 million in the same quarter of 2024, primarily due to the conclusion of the initial research term with Sanofi [4] - Research and development expenses increased to $86.1 million from $55.5 million year-over-year, reflecting accelerated clinical activities [5] - The net loss for the quarter was $86.4 million, or $1.03 per share, compared to a net loss of $49.0 million, or $0.67 per share, in the prior year [6] Pipeline and Collaborations - Nurix is also advancing other drug candidates, including Zelebrudomide for B-cell malignancies and NX-1607 for immuno-oncology indications, with ongoing clinical trials [7] - The company maintains strategic collaborations with Gilead, Sanofi, and Pfizer, focusing on various degrader programs and anticipating further updates throughout 2025 [7]